Doxorubicin
- PDF / 169,405 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 29 Downloads / 176 Views
1 S
Doxorubicin Cardiotoxicities: 3 case reports
In an analytical, observational, cross-sectional study of 30 patients, who underwent post neoadjuvant chemotherapy in 2019, three women [ages not stated] were described; they developed cardiotoxicities in the form of left ventricular diastolic dysfunction and pericardial effusion, mild mitral regurgitation or valvular heart disease following treatment with doxorubicin for locally advanced breast cancer. The women, who were diagnosed with locally advanced breast cancer, started receiving neoadjuvant chemotherapy with doxorubicin [routes and dosages not stated] for a period of 1 year. However, post-chemotherapy, echocardiography findings led to the diagnoses of left ventricular diastolic dysfunction and pericardial effusion (1 woman), mild mitral regurgitation (1 woman) and valvular heart disease (1 woman), which were attributed to the treatment with doxorubicin [times to reactions onsets and outcomes not stated]. Arditya R, et al. The relationship of vitamin D serum levels with the lowering of the left ventricular systolic function in women with locally advanced breast cancer undergoing doxorubicin chemotherapy. Systematic Reviews in Pharmacy 11: 983-986, No. 6, Jul 2020. Available from: URL: http://doi.org/10.31838/ srp.2020.6.139
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803514796
Reactions 14 Nov 2020 No. 1830
Data Loading...
